Unknown

Dataset Information

0

Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis.

ABSTRACT: Endocannabinoids acting on the cannabinoid-1 receptor (CB1R) or ghrelin acting on its receptor (GHS-R1A) both promote alcohol-seeking behavior, but an interaction between the two signaling systems has not been explored. Here, we report that the peripheral CB1R inverse agonist JD5037 reduces ethanol drinking in wild-type mice but not in mice lacking CB1R, ghrelin peptide or GHS-R1A. JD5037 treatment of alcohol-drinking mice inhibits the formation of biologically active octanoyl-ghrelin without affecting its inactive precursor desacyl-ghrelin. In ghrelin-producing stomach cells, JD5037 reduced the level of the substrate octanoyl-carnitine generated from palmitoyl-carnitine by increasing fatty acid ?-oxidation. Blocking gastric vagal afferents abrogated the ability of either CB1R or GHS-R1A blockade to reduce ethanol drinking. We conclude that blocking CB1R in ghrelin-producing cells reduces alcohol drinking by inhibiting the formation of active ghrelin and its signaling via gastric vagal afferents. Thus, peripheral CB1R blockade may have therapeutic potential in the treatment of alcoholism.

SUBMITTER: Godlewski G 

PROVIDER: S-EPMC6551287 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Endocannabinoids acting on the cannabinoid-1 receptor (CB<sub>1</sub>R) or ghrelin acting on its receptor (GHS-R<sub>1A</sub>) both promote alcohol-seeking behavior, but an interaction between the two signaling systems has not been explored. Here, we report that the peripheral CB<sub>1</sub>R inverse agonist JD5037 reduces ethanol drinking in wild-type mice but not in mice lacking CB<sub>1</sub>R, ghrelin peptide or GHS-R<sub>1A</sub>. JD5037 treatment of alcohol-drinking mice inhibits the forma  ...[more]

Similar Datasets

Unknown Cannabinoid CB<sub>1</sub> Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity.
| S-EPMC6597959 | biostudies-literature
Unknown Promoting activity of (α4)<sub>3</sub>(β2)<sub>2</sub> nicotinic cholinergic receptors reduces ethanol consumption.
| S-EPMC6901472 | biostudies-literature
Unknown Opposite effects of cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptors on antipsychotic clozapine-induced cardiotoxicity.
| S-EPMC6433645 | biostudies-literature
Unknown Opioid-sparing effects of cannabinoids on morphine analgesia: participation of CB<sub>1</sub> and CB<sub>2</sub> receptors.
| S-EPMC6692585 | biostudies-literature
Unknown Differential hepatoprotective role of the cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptors in paracetamol-induced liver injury.
| S-EPMC7312315 | biostudies-literature
Unknown Design, synthesis, and evaluation of substituted alkylindoles that activate G protein-coupled receptors distinct from the cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptors.
| S-EPMC10917149 | biostudies-literature
Unknown The peripheral CB<sub>1</sub> receptor antagonist JD5037 attenuates liver fibrosis via a CB<sub>1</sub> receptor/β-arrestin1/Akt pathway.
| S-EPMC7236068 | biostudies-literature
Unknown A time-dependent contribution of hippocampal CB<sub>1</sub> , CB<sub>2</sub> and PPARγ receptors to cannabidiol-induced disruption of fear memory consolidation.
| S-EPMC7024734 | biostudies-literature
Unknown Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB<sub>1</sub> /CB<sub>2</sub> versus GPR55 receptors.
| S-EPMC7070166 | biostudies-literature
Unknown The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB<sub>2</sub> Receptors.
| S-EPMC8889005 | biostudies-literature